#2462 - Aaron Siri

What It Covers

Attorney Aaron Siri, managing partner of a 100-person law firm specializing in vaccine litigation, explains how the 1986 National Childhood Vaccine Injury Act granted pharmaceutical companies unique immunity from design defect lawsuits, eliminating the economic incentive to improve vaccine safety, while presenting CDC and FDA data on pre-vaccine disease mortality, clinical trial standards, and government censorship during COVID-19.

Key Questions Answered

• •1986 Liability Shield: The National Childhood Vaccine Injury Act removed all design defect liability from childhood vaccine manufacturers — the only product category in America with this protection. Before 1986, only three routine vaccines existed, and every manufacturer had gone out of business due to injury claims. Rather than requiring safer products, Congress granted permanent immunity covering all future childhood vaccines, eliminating the core economic mechanism that forces every other industry to improve product safety.
• •Clinical Trial Double Standard: Pfizer's four most profitable drugs each underwent two to seven years of placebo-controlled safety trials before licensing. By contrast, most routine childhood vaccines received only days or weeks of safety review, and not a single routinely injected childhood vaccine — except the COVID-19 pediatric vaccine — was licensed based on a placebo-controlled trial. Siri states this is documented in FDA licensure literature and catalogued by vaccine in chapter ten of his book, *Vaccines: Amen*.
• •Pre-Vaccine Measles Mortality: CDC mortality records show approximately 400 Americans died annually from measles in the years immediately before the 1963 vaccine introduction — roughly one death per 450,000 Americans. Additionally, measles mortality had already declined over 98% between 1900 and the early 1960s due to improved sanitation, living conditions, and acute medical care, before any vaccine existed. This data point is publicly available on the CDC website and undermines claims that the vaccine alone prevented mass casualties.
• •Measles Infection and Long-Term Health: Multiple published PubMed studies, including a 22-year Japanese government-funded prospective study tracking 100,000 people, found that individuals who had natural measles and mumps infections showed a statistically significant 20% reduction in cardiovascular disease deaths. Separate studies show those without prior measles infection have a 66% higher rate of non-Hodgkin's lymphoma and a 266% higher rate of Hodgkin's lymphoma. Siri argues these findings raise unexamined public health tradeoffs in eliminating childhood febrile infections.
• •Influenza Vaccine and Respiratory Risk: Several published studies show that influenza-vaccinated individuals experience three to four times the rate of non-influenza respiratory infections compared to unvaccinated individuals, even when influenza-specific infection rates decrease. These findings are statistically significant across multiple retrospective epidemiological studies. Siri argues this data receives minimal attention because it is inconvenient to the prevailing narrative, and that net respiratory illness burden may not decrease — and could increase — with widespread influenza vaccination.
• •Hepatitis B Vaccine at Birth: Denmark administers the hepatitis B vaccine only when the mother tests hepatitis B positive, resulting in a childhood vaccination rate near 0.1%. The US mandates universal hepatitis B vaccination on the first day of life. Siri states that childhood hepatitis B rates between the two countries show no statistically significant difference, while the US carries additional risk: a newborn death adjudicated by the federal Vaccine Injury Compensation Program as caused by the hepatitis B vaccine. The VICP has paid approximately $5 billion in total damages.
• •Regulatory Capture and Revolving Door: Former CDC Director Julie Gerberding oversaw regulatory decisions involving Merck vaccine products during her tenure, then left to become a senior executive at Merck, reportedly earning tens of millions of dollars. A recorded Pfizer executive acknowledged that FDA staff avoid damaging industry relationships because they anticipate future private-sector employment. Federal agencies pass thousands of regulations annually — often exceeding congressional output of roughly 200 laws per year — with the regulated industries holding the greatest resources to influence those unelected regulators.